These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19254917)

  • 21. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.
    Lu TY; Jónsdóttir T; van Vollenhoven RF; Isenberg DA
    Ann Rheum Dis; 2008 Oct; 67(10):1493-4. PubMed ID: 18791057
    [No Abstract]   [Full Text] [Related]  

  • 22. [The treatment of autoimmune myositis with R-74].
    Petrányi G; Szegedi G
    Orv Hetil; 1970 Dec; 111(52):3074-6. PubMed ID: 4924845
    [No Abstract]   [Full Text] [Related]  

  • 23. Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy.
    Quartuccio L; Salvin S; Fabris M; Sacco S; De Vita S
    Ann Rheum Dis; 2008 Oct; 67(10):1494-5. PubMed ID: 18791058
    [No Abstract]   [Full Text] [Related]  

  • 24. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy.
    Benveniste O; Drouot L; Jouen F; Charuel JL; Bloch-Queyrat C; Behin A; Amoura Z; Marie I; Guiguet M; Eymard B; Gilbert D; Tron F; Herson S; Musset L; Boyer O
    Arthritis Rheum; 2011 Jul; 63(7):1961-71. PubMed ID: 21400483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy.
    Landon-Cardinal O; Allard-Chamard H; Chapdelaine H; Doucet S; Rich É; Bourré-Tessier J
    Ann Rheum Dis; 2023 Apr; 82(4):579-580. PubMed ID: 36609342
    [No Abstract]   [Full Text] [Related]  

  • 26. Usefulness of anti-SRP antibody testing in inflammatory myopathies.
    Wendling D; Guillot X; Godfrin-Valnet M; Prati C
    Joint Bone Spine; 2014 Dec; 81(6):548-9. PubMed ID: 24956983
    [No Abstract]   [Full Text] [Related]  

  • 27. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients.
    Suzuki S; Nishikawa A; Kuwana M; Nishimura H; Watanabe Y; Nakahara J; Hayashi YK; Suzuki N; Nishino I
    Orphanet J Rare Dis; 2015 May; 10():61. PubMed ID: 25963141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-74 treatment of autoimmune myositis.
    Petrányi G; Szegedi G
    Acta Med Acad Sci Hung; 1970; 27(4):351-6. PubMed ID: 5516086
    [No Abstract]   [Full Text] [Related]  

  • 29. B lymphocytes in nonorgan-specific autoimmune diseases: implications for therapy.
    Youinou P; Pers JO
    Lupus; 2012 Nov; 21(13):1375-7. PubMed ID: 22976931
    [No Abstract]   [Full Text] [Related]  

  • 30. Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network.
    Keren Z; Braun-Moscovici Y; Markovits D; Rozin A; Nahir M; Balbir-Gurman A; Melamed D
    Clin Immunol; 2009 Oct; 133(1):108-16. PubMed ID: 19632157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies.
    Zhao Y; Zhang W; Liu Y; Wang Z; Yuan Y
    Orphanet J Rare Dis; 2020 Jul; 15(1):181. PubMed ID: 32641139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Necrotising myopathy associated with anti-signal recognition particle (anti-SRP) antibody.
    De Souza FHC; Miossi R; Shinjo SK
    Clin Exp Rheumatol; 2017; 35(5):766-771. PubMed ID: 28281460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report.
    Kasher-Meron M; Uziel Y; Amital H
    Rheumatology (Oxford); 2009 Apr; 48(4):445-6. PubMed ID: 19164423
    [No Abstract]   [Full Text] [Related]  

  • 34. No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice.
    Dörner T; Burmester GR
    Rheumatology (Oxford); 2007 Apr; 46(4):563-4. PubMed ID: 17337751
    [No Abstract]   [Full Text] [Related]  

  • 35. Necrotizing autoimmune myopathy.
    Liang C; Needham M
    Curr Opin Rheumatol; 2011 Nov; 23(6):612-9. PubMed ID: 21885975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-SRP myopathy].
    Suzuki S
    Rinsho Shinkeigaku; 2011 Nov; 51(11):961-3. PubMed ID: 22277439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab in Churg-Strauss syndrome.
    Koukoulaki M; Smith KG; Jayne DR
    Ann Rheum Dis; 2006 Apr; 65(4):557-9. PubMed ID: 16531558
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune-mediated necrotizing myopathy.
    Bergua C; Chiavelli H; Simon JP; Boyer O; Jouen F; Stenzel W; Martinet J
    Z Rheumatol; 2016 Mar; 75(2):151-6. PubMed ID: 26783154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.
    Chiu YE; Co DO
    Pediatr Dermatol; 2011; 28(4):357-67. PubMed ID: 21793879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?
    Simms RW; Lafyatis R
    Rheumatology (Oxford); 2010 Feb; 49(2):201-2. PubMed ID: 20032221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.